Emmanouil Pikoulis1, Georgios A Margonis2, Nikolaos Andreatos3, Kazunari Sasaki3, Anastasios Angelou1, Georgios Polychronidis4, Anastasia Pikouli1, Elena Riza5, Timothy M Pawlik3, Efstathios Antoniou6. 1. First Department of Surgery, Laiko Hospital, University of Athens, Athens, Greece. 2. Department of Surgery, Johns Hopkins University, Baltimore, MD, U.S.A. gmargon1@jhu.edu. 3. Department of Surgery, Johns Hopkins University, Baltimore, MD, U.S.A. 4. Department of General, Abdominal and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany. 5. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 6. Second Department of Propaedeutic Surgery, Laiko Hospital, University of Athens, Athens, Greece.
Abstract
BACKGROUND/AIMS: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. MATERIALS AND METHODS: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. RESULTS: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. CONCLUSION: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered. Copyright
BACKGROUND/AIMS: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. MATERIALS AND METHODS: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. RESULTS: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. CONCLUSION:BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered. Copyright
Authors: George Zarkavelis; Stergios Boussios; Alexandra Papadaki; Konstantinos H Katsanos; Dimitrios K Christodoulou; George Pentheroudakis Journal: Ann Gastroenterol Date: 2017-09-22